Drug Trial Radar · NCT05653323
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Dec 14, 2022
Primary completion
Sep 12, 2023
Study completion Sep 12, 2023
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-993 at different doses in healthy participants.
Conditions
- Pain
Interventions
VX-993Drug
Suspension for oral administration.
PlaceboDrug
Suspension for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 25
- Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 25
- Part B: Safety and Tolerability as Assessed by Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) ResponsesTime frame: Pre-dose up to Day 25
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MAC Clinical Research
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.